Search results for "antibody"
Article
Register to the Chromatography + Filtration Virtual Summit 2024
Learn from presentations, live Q&A, and panel discussions with your peers on recent advances in antibody, antibody variants, recombinant proteins, and gene therapy downstream applications.
Agen…
Article
Reimagining Affordable Biosimilars
With the ever-growing therapeutic modalities (such as bi-functional molecule, antibody-drug conjugates, cell and gene therapies) (1) along with advanced analytical tools to measure primary, secondary,…
Article
Modeling the Degradation of mAb Therapeutics
FDA has approved a number of these antibody drug molecules, which are in various stages of clinical and pre-clinical development. But since the major constituent of the final drug product is protein, …
Article
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic Drugs
For example, a typical monoclonal antibody N-glycan sample may generate a dozen or more peaks in a UHPLC-FLR-MS profile. Each peak may or may not change upon treatment with an exoglysosidase. Thus, ea…
Article
The Challenge of Disruptive Technologies in Bioprocessing
An example of the latter may be the use of affinity chromatography in the capture step of antibody processes, Jagschies says.
“When we look at the biologics market dynamics for treatment of dis…
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
Cytiva stated in a recent press release that a new standard for monoclonal antibody purification is being set. Can you elaborate on that?
At Cytiva, we felt that with our knowledge and experience…
Article
N-Glycan Analysis of Biotherapeutic Proteins
N-glycans of antibody and antibody-derived biotherapeutics
The influence of N-glycans on the efficacy, stability, half-life, and safety of antibody and antibody-derived biotherapeutics are well-re…
Article
Cost Considerations Drive Lean Technology in Biopharmaceutical Manufacturing
The Fab region of an antibody interacts with the target, while the Fc is engaged in cell-mediated cytotoxicity. Under EMA regulations,
in-vitro studies must show that the antibody binds to the tar…
Article
Platform Approach Speeds Process Development
For antibody process development and production, maintaining desired quality attributes while reducing time from DNA to market, maintaining cost effectiveness, and providing manufacturing flexibility …
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
It has been observed that several engineered antibody genes expressed in CHO cells -produced unintended transcripts—resulting from aberrant RNA splicing at cryptic splicing sites—in addition to the ex…